Size | Price | Stock | Qty |
---|---|---|---|
1mg |
|
||
5mg |
|
||
10mg |
|
||
Other Sizes |
|
ln Vitro |
LAH4 TFA is able to compound DNA, bind to the cell surface membrane, and, when enclosed in an endosome, cause the endosomal membrane to rupture when the pH falls[1]. LAH4 TFA exhibits strong transfection capabilities for plasmid DNA. A human cell line can be effectively treated with siRNAs in vitro by peptides belonging to the LAH4 family[2]. Through mechanisms involving endosomal acidification and processing via the proteasome pathway, LAH4 TFA is found to mediate the intracellular delivery of both protein and nucleotide cargo. This facilitates protein internalization and leads to enhanced cross presentation of protein antigen by dendritic cells to CD8+ T cells. Additionally, LAH4 TFA enhances CpG internalization, which causes NF-kB activation and amplifies CpG's adjuvant effect[3]. Bacillus subtilis and Escherichia coli are resistant to the antibacterial properties of LAH4 TFA. However, human red blood cells are not lysed by the peptide at bacteriocidal doses. When comparing pH 5 to pH 7.5, the antibacterial activity of LAH4 TFA are two orders of magnitude more pronounced[4].
|
---|---|
References |
[1]. Mason AJ, et al. The antibiotic and DNA-transfecting peptide LAH4 selectively associates with, and disorders, anionic lipids in mixed membranes. FASEB J. 2006;20(2):320-322.
[2]. Langlet-Bertin B, et al. Design and evaluation of histidine-rich amphipathic peptides for siRNA delivery. Pharm Res. 2010;27(7):1426-1436. [3]. Zhang TT, et al. LAH4 enhances CD8+ T cell immunity of protein/peptide-based vaccines. Vaccine. 2012;30(4):784-793. |
Molecular Formula |
C134H229F3N38O29
|
---|---|
Molecular Weight |
2893.55
|
Related CAS # |
LAH4;184776-51-0
|
Appearance |
Typically exists as solids (or liquids in special cases) at room temperature
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
H2O :~100 mg/mL (~34.56 mM)
|
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: 25 mg/mL (8.64 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
 (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 0.3456 mL | 1.7280 mL | 3.4560 mL | |
5 mM | 0.0691 mL | 0.3456 mL | 0.6912 mL | |
10 mM | 0.0346 mL | 0.1728 mL | 0.3456 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.